Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD7 CAR-T cells RD13-02

A preparation of T lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) directed against the tumor-associated antigen (TAA) CD7, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD7 CAR-T cells RD13-02 specifically target and kill CD7-expressing tumor cells. CD7 is a transmembrane glycoprotein expressed by T cells and natural killer (NK) cells and their precursors. It is expressed in the majority of lymphoblastic T-cell leukemias and lymphomas and in a subset of peripheral T-cell lymphomas.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD7 CAR T cells RD13-02
anti-CD7 CAR T cells RD13-02
CD7 CAR-T cells RD13-02
Code name:RD13 02
RD13-02
RD1302
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search